Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma

RCT (n=1069) found lenvatinib with pembrolizumab (median, 23.9 months, HR 0.39; 95% CI 0.32-0.49; P<0.001) or with everolimus (14.7 months, HR 0.65; 95% CI 0.53 to 0.80; P<0.001) was linked to significantly longer progression-free survival vs sunitinib (9.2 months).

Source:

New England Journal of Medicine